390 related articles for article (PubMed ID: 31281492)
41. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.
Galimi F; Torti D; Sassi F; Isella C; Corà D; Gastaldi S; Ribero D; Muratore A; Massucco P; Siatis D; Paraluppi G; Gonella F; Maione F; Pisacane A; David E; Torchio B; Risio M; Salizzoni M; Capussotti L; Perera T; Medico E; Di Renzo MF; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2011 May; 17(10):3146-56. PubMed ID: 21447729
[TBL] [Abstract][Full Text] [Related]
42. Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization.
Zou J; Liu Y; Wang J; Liu Z; Lu Z; Chen Z; Li Z; Dong B; Huang W; Li Y; Gao J; Shen L
J Transl Med; 2018 Jan; 16(1):15. PubMed ID: 29370817
[TBL] [Abstract][Full Text] [Related]
43. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
Chen D; Huang X; Cai J; Guo S; Qian W; Wery JP; Li QX
Oncotarget; 2015 Dec; 6(38):40815-21. PubMed ID: 26512781
[TBL] [Abstract][Full Text] [Related]
44. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
[TBL] [Abstract][Full Text] [Related]
45. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.
Garralda E; Paz K; López-Casas PP; Jones S; Katz A; Kann LM; López-Rios F; Sarno F; Al-Shahrour F; Vasquez D; Bruckheimer E; Angiuoli SV; Calles A; Diaz LA; Velculescu VE; Valencia A; Sidransky D; Hidalgo M
Clin Cancer Res; 2014 May; 20(9):2476-84. PubMed ID: 24634382
[TBL] [Abstract][Full Text] [Related]
46. Fidelity of a PDX-CR model for bladder cancer.
Mondal AM; Ma AH; Li G; Krawczyk E; Yuan R; Lu J; Schlegel R; Stamatakis L; Kowalczyk KJ; Philips GK; Pan CX; Liu X
Biochem Biophys Res Commun; 2019 Sep; 517(1):49-56. PubMed ID: 31303270
[TBL] [Abstract][Full Text] [Related]
47. Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts.
Moy RH; Walch HS; Mattar M; Chatila WK; Molena D; Strong VE; Tang LH; Maron SB; Coit DG; Jones DR; Hechtman JF; Solit DB; Schultz N; de Stanchina E; Janjigian YY
JCO Precis Oncol; 2022 Feb; 6():e2100242. PubMed ID: 35138918
[TBL] [Abstract][Full Text] [Related]
48. Patient-derived xenografts undergo mouse-specific tumor evolution.
Ben-David U; Ha G; Tseng YY; Greenwald NF; Oh C; Shih J; McFarland JM; Wong B; Boehm JS; Beroukhim R; Golub TR
Nat Genet; 2017 Nov; 49(11):1567-1575. PubMed ID: 28991255
[TBL] [Abstract][Full Text] [Related]
49. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M
Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799
[TBL] [Abstract][Full Text] [Related]
50. Patient-Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy.
Mo S; Tang P; Luo W; Zhang L; Li Y; Hu X; Ma X; Chen Y; Bao Y; He X; Fu G; Xu X; Rao X; Li X; Guan R; Chen S; Deng Y; Lv T; Mu P; Zheng Q; Wang S; Liu F; Li Y; Sheng W; Huang D; Hu C; Gao J; Zhang Z; Cai S; Clevers H; Peng J; Hua G
Adv Sci (Weinh); 2022 Nov; 9(31):e2204097. PubMed ID: 36058001
[TBL] [Abstract][Full Text] [Related]
51. Metformin Inhibits Cellular Proliferation and Bioenergetics in Colorectal Cancer Patient-Derived Xenografts.
Mohamed Suhaimi NA; Phyo WM; Yap HY; Choy SHY; Wei X; Choudhury Y; Tan WJ; Tan LAPY; Foo RSY; Tan SHS; Tiang Z; Wong CF; Koh PK; Tan MH
Mol Cancer Ther; 2017 Sep; 16(9):2035-2044. PubMed ID: 28533437
[TBL] [Abstract][Full Text] [Related]
52. Patient-derived xenograft models of breast cancer and their predictive power.
Whittle JR; Lewis MT; Lindeman GJ; Visvader JE
Breast Cancer Res; 2015 Feb; 17(1):17. PubMed ID: 25849559
[TBL] [Abstract][Full Text] [Related]
53. Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients.
Oh BY; Lee WY; Jung S; Hong HK; Nam DH; Park YA; Huh JW; Yun SH; Kim HC; Chun HK; Cho YB
Oncotarget; 2015 Jun; 6(18):16059-68. PubMed ID: 25965827
[TBL] [Abstract][Full Text] [Related]
54. Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs.
Punzi S; Meliksetian M; Riva L; Marocchi F; Pruneri G; Criscitiello C; Orsi F; Spaggiari L; Casiraghi M; Della Vigna P; Luzi L; Curigliano G; Pelicci PG; Lanfrancone L
Cells; 2019 Jun; 8(6):. PubMed ID: 31216647
[TBL] [Abstract][Full Text] [Related]
55. Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models.
Prasetyanti PR; van Hooff SR; van Herwaarden T; de Vries N; Kalloe K; Rodermond H; van Leersum R; de Jong JH; Franitza M; Nürnberg P; Todaro M; Stassi G; Medema JP
Int J Cancer; 2019 Jan; 144(2):366-371. PubMed ID: 30151914
[TBL] [Abstract][Full Text] [Related]
56. Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer.
Bonazzi VF; Kondrashova O; Smith D; Nones K; Sengal AT; Ju R; Packer LM; Koufariotis LT; Kazakoff SH; Davidson AL; Ramarao-Milne P; Lakis V; Newell F; Rogers R; Davies C; Nicklin J; Garrett A; Chetty N; Perrin L; Pearson JV; Patch AM; Waddell N; Pollock PM
Genome Med; 2022 Jan; 14(1):3. PubMed ID: 35012638
[TBL] [Abstract][Full Text] [Related]
57. High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer.
Tan IB; Malik S; Ramnarayanan K; McPherson JR; Ho DL; Suzuki Y; Ng SB; Yan S; Lim KH; Koh D; Hoe CM; Chan CY; Ten R; Goh BK; Chung AY; Tan J; Chan CX; Tay ST; Alexander L; Nagarajan N; Hillmer AM; Tang CL; Chua C; Teh BT; Rozen S; Tan P
Genome Biol; 2015 Feb; 16(1):32. PubMed ID: 25808843
[TBL] [Abstract][Full Text] [Related]
58. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
59. Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers.
Cho SY; Chae J; Na D; Kang W; Lee A; Min S; Kang J; Choi B; Lee J; Sung CO; Chuang JH; Lee C; Lee WS; Park H; Kim JI
Clin Cancer Res; 2019 May; 25(9):2821-2834. PubMed ID: 30670495
[TBL] [Abstract][Full Text] [Related]
60. Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study.
Nemati F; de Koning L; Gentien D; Assayag F; Henry E; Ait Rais K; Pierron G; Mariani O; Nijnikoff M; Champenois G; Nicolas A; Meseure D; Gardrat S; Servant N; Hupé P; Kamal M; Le Tourneau C; Piperno-Neumann S; Rodrigues M; Roman-Roman S; Decaudin D; Mariani P; Cassoux N
Curr Oncol; 2023 Oct; 30(10):9090-9103. PubMed ID: 37887557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
